title: Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).
abstract: A series of imidazo[1,2-a]pyridine analogs that effectively inhibit cholesterol 24-hydroxylase (CYP46A1) was reported in WO2014061676. The treatment or prophylaxis of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by these novel CYP46A1 inhibitors is claimed in the patent. These compounds represent a novel pharmacophore that is different from other structural motifs described in the prior patent publications by Takeda Pharmaceutical Company Ltd.
authors.affiliation: Daiichi Sankyo Co., Ltd., Venture Science Laboratories , 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710 , Japan +813 3492 3131 ; +813 5436 8563 ; uto.yoshikazu.pw@daiichisankyo.co.jp.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Uto
mesh_terms: D000818:Animals; D000072556:Cholesterol 24-Hydroxylase; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology; D010330:Patents as Topic; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology*; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors*
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D011725:Pyridines; D013250:Steroid Hydroxylases; D000072556:Cholesterol 24-Hydroxylase; C001439:imidazo(1,2-a)pyridine
keywords: Alzheimer’s disease; CYP46A1; cholesterol 24-hydroxylase; imidazopyridine